Home › Funds › Sofinnova Investments, Inc. › SUPN
Sofinnova Investments, Inc. position in SUPN
SUPERNUS PHARMACEUTICALS · Health Care
Sofinnova Investments, Inc. reported holding 1,036,328 shares of SUPN (SUPERNUS PHARMACEUTICALS) in its Q2 2026 13F filing — a position valued at US$48.2M, representing 2.57% of its reported portfolio and ranking #10 among its reported holdings. Sofinnova Investments, Inc. has disclosed SUPN holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Sofinnova Investments, Inc.'s SUPN position evolved
Sofinnova Investments, Inc. first disclosed a stake in SUPN in Q1 2025 at 520,678 shares (US$17.1M). The position peaked in Q1 2026 at 954,309 shares, worth US$49.3M. Across 6 filings, Sofinnova Investments, Inc. increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,036,328 shares valued at US$48.2M — an increase of 82,019 shares quarter over quarter.. Notable position changes include a 54% increase in Q2 2025 (shares rose 52% over the following quarter), a 53% trim in Q3 2025 (shares rose 4% over the following quarter), a 73% increase in Q1 2026 (shares fell 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 520.68K | $17.05M | New |
| Q2 2025 | 799.25K | $25.19M | Add |
| Q3 2025 | 377.07K | $18.02M | Reduce |
| Q4 2025 | 553.10K | $27.49M | Add |
| Q1 2026 | 954.31K | $49.33M | Add |
| Q2 2026 | 1.04M | $48.20M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SUPN and 13F data
SUPN (SUPERNUS PHARMACEUTICALS) is a Health Care company. 34 other funds we track also report a position in SUPN — the largest reported positions include MILLENNIUM MANAGEMENT LLC (US$179.2M), ARMISTICE CAPITAL, LLC (US$123.1M), ASHFORD CAPITAL MANAGEMENT INC (US$28.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SUPN
- MILLENNIUM MANAGEMENT LLC 3.85M sh · $179.21M · Q2 2026
- ARMISTICE CAPITAL, LLC 2.65M sh · $123.07M · Q2 2026
- ASHFORD CAPITAL MANAGEMENT INC 613.78K sh · $28.55M · Q2 2026
- Soleus Capital Management, L.P. 520.00K sh · $24.19M · Q2 2026
- RICE HALL JAMES & ASSOCIATES, LLC 490.22K sh · $22.80M · Q2 2026
More on Sofinnova Investments, Inc.
FAQ
How long has Sofinnova Investments, Inc. held SUPN?
Sofinnova Investments, Inc. has disclosed SUPN holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
What is Sofinnova Investments, Inc.'s current position in SUPN?
As of Q2 2026, Sofinnova Investments, Inc. holds 1.04M shares of SUPN (SUPERNUS PHARMACEUTICALS), valued at $48.20M, representing 2.57% of its reported portfolio and ranking #10.
Has Sofinnova Investments, Inc. been buying or selling SUPN?
In the latest 13F filing (Q2 2026), Sofinnova Investments, Inc. increased its position in SUPN. The position peaked in Q1 2026 at 954.31K shares.
Which other funds hold SUPN?
Other major institutional holders of SUPN include MILLENNIUM MANAGEMENT LLC, ARMISTICE CAPITAL, LLC, ASHFORD CAPITAL MANAGEMENT INC, among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.